Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT)

P. Connor, M.S. van Kammen, A.W.A. Lensing, E. Chalmers, K. Kallay, K. Hege, P. Simioni, T. Biss, F. Bajolle, D. Bonnet, S. Grunt, R. Kumar, O. Lvova, R. Bhat, A. Van Damme, J. Palumbo, A. Santamaria, P. Saracco, J. Payne, S. BairdK. Godder, V. Labarque, C. Male, I. Martinelli, M.M. Soto, J. Motwani, S. Shah, H.L. Hooimeijer, M.H. Prins, D. Kubitza, W.T. Smith, S.D. Berkowitz, A.F. Pap, M. Majumder, P. Monagle, J.M. Coutinho, C.e.r.e.b.r.a.l. EINSTEIN-Jr, EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)6250-6258
Number of pages9
JournalBlood advances
Volume4
Issue number24
DOIs
Publication statusPublished - 22 Dec 2020

Keywords

  • anticoagulant treatment
  • children
  • definition
  • diagnosis
  • guideline
  • heparin
  • oral rivaroxaban
  • risk-factors
  • sinovenous thrombosis
  • DEFINITION
  • DIAGNOSIS
  • ORAL RIVAROXABAN
  • RISK-FACTORS
  • HEPARIN
  • GUIDELINE
  • CHILDREN
  • SINOVENOUS THROMBOSIS
  • ANTICOAGULANT TREATMENT

Cite this